The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease

Clinical and Experimental Immunology

Volumn 156, Issue 1, 2009, Pages 172-182

  Inoue, S ^b   Nakase, H ^a,b   Matsuura, M ^b   Mikami, S ^b   Ueno, S ^b   Uza, N ^b   Chiba, T ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Epithelial regeneration; IBD; MDR1; NF B; Proteasome inhibitor

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENTERITIS; EPITHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL PROLIFERATION; COLON; CYSTEINE PROTEINASE INHIBITORS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINAL MUCOSA; LEUPEPTINS; MICE; MICE, INBRED C57BL; RNA, MESSENGER; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61849110417     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03872.x     Document Type: Article

References (42)

1. Sellon RK, Tonkonogy S, Schultz M et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998 66 : 5224 31.
2. Kim SC, Tonkonogy SL, Albright CA et al. Variable phenotype of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005 128 : 891 906.
3. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994 106 : 533 9.
4. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-Β by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989 30 : 835 8.
5. Reinecker HC, Steffen M, Witthoeft T et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993 94 : 174 81.
6. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994 106 : 1455 66.
7. Schmid RM, Adler G. NF-κB/Rel/IκB: implications in gastrointestinal diseases. Gastroenterology 2000 118 : 1208 28.
8. Karin M, Ben Neriah Y. Phospholylation meets ubiquitination: the control of NF-kappa B activity. Annu Rev Immunol 2000 18 : 621 63.
9. Ghosh S, Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990 344 : 678 82.
10. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 1993 365 : 182 5.
11. Ghosh S, Karin M. Missing pieces in the NF-kappa B puzzle. Cell 2002 109 (Suppl S81 96.
12. Hayden MS, Ghosh S. Signaling to NF-kappa B. Genes Dev 2004 18 : 2195 224.
13. Krappmann D, Scheidereit C. A pervasive role of ubiquitin conjugation in activation and termination of Ikappa B kinase pathways. EMBO Rep 2005 6 : 321 6.
14. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor κB in inflammatory bowel disease. Gut 1998 42 : 477 84.
15. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996 2 : 998 1004.
16. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994 79 : 13 21.
17. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004 4 : 349 60.
18. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994 78 : 773 85.
19. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stablizes a newly phosphorylated form I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994 13 : 5433 41.
20. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1995 92 : 10599 603.
21. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003 81 : 235 45.
22. Visekruna A, Joeris T, Seidel D et al. Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006 116 : 3195 203.
23. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-κB in the resolution of inflammation. Nat Med 2001 7 : 1291 7.
24. Begue B, Wajant H, Bambou JC et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006 130 : 1962 74.
25. Francis NM, Jin W, Wahl SM. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-Β1 signaling pathway. J Immunol 2004 172 : 3814 21.
26. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990 98 : 694 702.
27. Williams KL, Fuller CR, Dieleman LA et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001 120 : 925 37.
28. Silva HJ, Gatter KC, Millard PR, Kettlewell M, Mortensen NJ, Jewell DP. Crypt cell proliferation and HLA-DR expression in pelvic ileal pouches. J Clin Pathol 1990 43 : 824 8.
29. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982 218 : 474 5.
30. 3H]-thymidine for studies of hepatocellular proliferation in rodents. Carcinogenesis 1989 10 : 1341 3.
31. Mccormack SA, Viar MJ, Johnson LR. Migration of IEC-6 cells: a model for mucosal healing. Am J Physiol 1992 263 : G426 435.
32. Ciacci C, Lind SE, Podolsky DK. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology 1993 105 : 93 101.
33. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997 337 : 1029 35.
34. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med 2003 348 : 24 32.
35. Rogler G, Brand K, Vogl D et al. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998 115 : 357 69.
36. Ruiz PA, Shkoda A, Kim SC, Sartor RB, Haller D. IL-10 gene-deficient mice lack TGF-Β/Smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic Enterococcus faecalis. Gastroenterology 2005 174 : 2990 9.
37. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993 69 : 238 49.
38. Dieleman LA, Ridman BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994 107 : 1643 52.
39. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002 71 : 537 92.
40. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003 52 : 759 66.
41. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998 161 : 5733 44.
42. Kuo MT, Liu Z, Wei Y et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 2002 21 : 1945 54.